Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt

Abstract Background Among those aged 20–74 in industrialized countries, diabetic retinopathy (DR) is the main cause of visual impairment. Diabetic macular edema (DME) is the leading cause of blindness in people with DR. DME that is resistant to therapy is now being treated with a number of different...

Full description

Saved in:
Bibliographic Details
Main Authors: Hossam Eldin M. A. Khalil, Hazem E. Haroun, Alaa A. I. Shalan, Waleed M. Mahran
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:Beni-Suef University Journal of Basic and Applied Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43088-025-00598-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585508384931840
author Hossam Eldin M. A. Khalil
Hazem E. Haroun
Alaa A. I. Shalan
Waleed M. Mahran
author_facet Hossam Eldin M. A. Khalil
Hazem E. Haroun
Alaa A. I. Shalan
Waleed M. Mahran
author_sort Hossam Eldin M. A. Khalil
collection DOAJ
description Abstract Background Among those aged 20–74 in industrialized countries, diabetic retinopathy (DR) is the main cause of visual impairment. Diabetic macular edema (DME) is the leading cause of blindness in people with DR. DME that is resistant to therapy is now being treated with a number of different management strategies. This research was to examine the efficacy of sub-tenon steroid and anti- vascular endothelial growth factor (VEGF) injections as a combination therapy for the treatment of resistant DME, owing to the synergistic effect of this combination. Methods This is a two-arm, randomized, prospective clinical trial that included 100 eyes of patients with refractory DME divided into 2 equal groups: group 1 received posterior subtenon triamcinolone (STTA) and anti-VEGF injections (0.5 mg ranibizumab), and group 2 received anti-VEGF injections (0.5 mg ranibizumab) only, in the same session. The 2 groups were followed up for a period of 6 months. Results Group 1 showed significant improvements in best corrected visual acuity (BCVA) (from 0.20 ± 0.11 to 0.32 ± 0.12, p = 0.04) and central macular thickness (CMT) (from 393.2 ± 35.29 to 260.2 ± 11.43 µm, p = 0.001), with fewer injections required compared to Group 2. Recurrence rates were significantly higher in Group 2 (42% vs. 12%, p = 0.026). After injections, there was a noticeable rise in intraocular pressure (IOP) (16.02 ± 1.56 Vs 16.26 ± 1.24 in both groups respectively). However, this elevation is usually just transitory lasting for short periods of time and is within the safe, insignificant rise ranges. Conclusion The use of combined therapy with anti-VEGF treatment and STTA has been found to be an effective and safe approach to managing resistant DME. The lower number of injections needed help to reduce the economic burden, especially under constrained financial circumstances.
format Article
id doaj-art-94faa4ed761e4a56b17466021793dcae
institution Kabale University
issn 2314-8543
language English
publishDate 2025-01-01
publisher SpringerOpen
record_format Article
series Beni-Suef University Journal of Basic and Applied Sciences
spelling doaj-art-94faa4ed761e4a56b17466021793dcae2025-01-26T12:47:40ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432025-01-0114111110.1186/s43088-025-00598-xCombination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in EgyptHossam Eldin M. A. Khalil0Hazem E. Haroun1Alaa A. I. Shalan2Waleed M. Mahran3Ophthalmology Department, Beni-Suef UniversityOphthalmology Department, Beni-Suef UniversityMemorial Institute for Ophthalmic ResearchOphthalmology Department, Beni-Suef UniversityAbstract Background Among those aged 20–74 in industrialized countries, diabetic retinopathy (DR) is the main cause of visual impairment. Diabetic macular edema (DME) is the leading cause of blindness in people with DR. DME that is resistant to therapy is now being treated with a number of different management strategies. This research was to examine the efficacy of sub-tenon steroid and anti- vascular endothelial growth factor (VEGF) injections as a combination therapy for the treatment of resistant DME, owing to the synergistic effect of this combination. Methods This is a two-arm, randomized, prospective clinical trial that included 100 eyes of patients with refractory DME divided into 2 equal groups: group 1 received posterior subtenon triamcinolone (STTA) and anti-VEGF injections (0.5 mg ranibizumab), and group 2 received anti-VEGF injections (0.5 mg ranibizumab) only, in the same session. The 2 groups were followed up for a period of 6 months. Results Group 1 showed significant improvements in best corrected visual acuity (BCVA) (from 0.20 ± 0.11 to 0.32 ± 0.12, p = 0.04) and central macular thickness (CMT) (from 393.2 ± 35.29 to 260.2 ± 11.43 µm, p = 0.001), with fewer injections required compared to Group 2. Recurrence rates were significantly higher in Group 2 (42% vs. 12%, p = 0.026). After injections, there was a noticeable rise in intraocular pressure (IOP) (16.02 ± 1.56 Vs 16.26 ± 1.24 in both groups respectively). However, this elevation is usually just transitory lasting for short periods of time and is within the safe, insignificant rise ranges. Conclusion The use of combined therapy with anti-VEGF treatment and STTA has been found to be an effective and safe approach to managing resistant DME. The lower number of injections needed help to reduce the economic burden, especially under constrained financial circumstances.https://doi.org/10.1186/s43088-025-00598-xDiabetic retinopathyMacular edemaSub-tenon triamcinoloneAnti-VEGFCombined therapy
spellingShingle Hossam Eldin M. A. Khalil
Hazem E. Haroun
Alaa A. I. Shalan
Waleed M. Mahran
Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
Beni-Suef University Journal of Basic and Applied Sciences
Diabetic retinopathy
Macular edema
Sub-tenon triamcinolone
Anti-VEGF
Combined therapy
title Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
title_full Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
title_fullStr Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
title_full_unstemmed Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
title_short Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
title_sort combination therapy of intravitreal ranibizumab and sub tenon triamcinolone for treatment of resistant diabetic macular edema a clinical study in egypt
topic Diabetic retinopathy
Macular edema
Sub-tenon triamcinolone
Anti-VEGF
Combined therapy
url https://doi.org/10.1186/s43088-025-00598-x
work_keys_str_mv AT hossameldinmakhalil combinationtherapyofintravitrealranibizumabandsubtenontriamcinolonefortreatmentofresistantdiabeticmacularedemaaclinicalstudyinegypt
AT hazemeharoun combinationtherapyofintravitrealranibizumabandsubtenontriamcinolonefortreatmentofresistantdiabeticmacularedemaaclinicalstudyinegypt
AT alaaaishalan combinationtherapyofintravitrealranibizumabandsubtenontriamcinolonefortreatmentofresistantdiabeticmacularedemaaclinicalstudyinegypt
AT waleedmmahran combinationtherapyofintravitrealranibizumabandsubtenontriamcinolonefortreatmentofresistantdiabeticmacularedemaaclinicalstudyinegypt